A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter study to evaluate the safety, tolerability, and immunogenicity of two doses of a H5N1 when administered to adult and elderly volunteers with and without immunosuppressive conditions

Trial Profile

A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter study to evaluate the safety, tolerability, and immunogenicity of two doses of a H5N1 when administered to adult and elderly volunteers with and without immunosuppressive conditions

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Influenza A virus H5N1 vaccines (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Seqirus
  • Most Recent Events

    • 13 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 03 Jun 2014 Planned End Date changed from 1 Feb 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top